The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing IV Ketamine and it’s treatment for acute suicidality, anti-depressant oral medication NRX-101 and the launch of Hope Therapeutics.
What Are NRX-101 and NRX-100? It’s against this backdrop that NRx Pharmaceuticals sought to develop two new pharmacological treatments for bipolar depression with a risk of suicide.
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing IV Ketamine and it’s treatment for acute suicidality, anti-depressant oral medication NRX-101 and the launch of Hope Therapeutics.
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing suicidal ideation, NRx-100, IV Ketamine, and the promising findings in Phase 2b/3 clinical trial of NRX-101 vs. Lurasidone for treatment of Suicidal Bipolar Depression.
One America News interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing how Ketamine can reduce Suicidal Ideation.
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing IV Ketamine and it’s treatment for acute suicidality, anti-depressant oral medication NRX-101 and the launch of Hope Therapeutics.
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing suicidal ideation, NRx-100 and IV Ketamine.
David Meltzer of “Office Hours” interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals to discuss the anti-depressant effect of Ketamine.
Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals, gives the keynote address “Ketamine for Suicidal Depression: The Benefits are Clear, But So are the Risks,” at the Sachs Neuroscience Innovation Forum in San Francisco, CA on January 7, 2024.
